Lifebit Unveils AI-Powered Platform to Safeguard Global Medical Data
London, Monday, 27 April 2026.
Today, Lifebit launched a pioneering AI system to instantly evaluate and secure biomedical data exports, accelerating global health research while ensuring strict privacy for millions of patients.
Automating Data Governance in Real-Time
Announced in London on April 26, 2026, Lifebit’s AI-Automated Airlock v2 functions as either a standalone solution or a fully integrated governance product for Trusted Research Environments (TREs) [1]. The system employs real-time artificial intelligence to assess biomedical data export requests, assigning a Red, Amber (sub-categorized into Low, Medium, and High), or Green (RAG) status [1]. This intelligent decisioning framework determines whether data should be automatically approved, rejected, or sent for manual review [1]. By actively scanning outputs for personally identifiable information (PII), sensitive data, and small participant counts, the platform ensures that privacy is maintained without creating administrative bottlenecks that typically slow down critical research [1].
Strengthening Federated Infrastructure
Alongside the Airlock v2 release, Lifebit also introduced “System Health Observability” to its federated platform [2]. This parallel feature is designed to provide continuous operational governance and security posture management for TREs, moving organizations away from fragmented manual oversight [2]. Built around the ONS Five Safes framework, Lifebit’s architecture ensures that data remains securely at its source and sovereignty stays with the data controller, while only safe, compliant outputs pass through the AI airlock [2].
Global Scale and Industry Impact
These technological advancements are being deployed at a massive global scale. Privately held and headquartered in New York, Lifebit currently manages and analyzes over 275 million patient records across 30 countries, representing an average baseline of over 9.167 million records per operating nation [1][2]. Founded in 2017 and operating with a core workforce of between 51 and 200 employees, the biotechnology firm supports national-scale biomedical research for high-profile public entities, including the USA-NIH, Genomics England, and Singapore’s Ministry of Health [1][2]. In the private sector, its federated infrastructure is utilized by pharmaceutical giants like Boehringer Ingelheim and major healthcare enterprises including UnitedHealth Group, FlatIron Health, and 23andMe [1].